Logo image of ADMA

ADMA BIOLOGICS INC (ADMA) Stock Fundamental Analysis

NASDAQ:ADMA - Nasdaq - US0008991046 - Common Stock - Currency: USD

20.64  -0.96 (-4.44%)

Fundamental Rating

7

Taking everything into account, ADMA scores 7 out of 10 in our fundamental rating. ADMA was compared to 559 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is not overvalued while it is showing excellent growth. This is an interesting combination. These ratings would make ADMA suitable for growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA reported 4 times negative net income.
In multiple years ADMA reported negative operating cash flow during the last 5 years.
ADMA Yearly Net Income VS EBIT VS OCF VS FCFADMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of 40.50%, ADMA belongs to the top of the industry, outperforming 99.11% of the companies in the same industry.
ADMA has a Return On Equity of 55.37%. This is amongst the best in the industry. ADMA outperforms 98.75% of its industry peers.
ADMA has a Return On Invested Capital of 26.28%. This is amongst the best in the industry. ADMA outperforms 98.75% of its industry peers.
Industry RankSector Rank
ROA 40.5%
ROE 55.37%
ROIC 26.28%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ADMA Yearly ROA, ROE, ROICADMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

1.3 Margins

ADMA has a better Profit Margin (45.01%) than 98.93% of its industry peers.
ADMA's Operating Margin of 33.10% is amongst the best of the industry. ADMA outperforms 97.85% of its industry peers.
ADMA's Gross Margin of 52.58% is fine compared to the rest of the industry. ADMA outperforms 77.64% of its industry peers.
ADMA's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 33.1%
PM (TTM) 45.01%
GM 52.58%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
ADMA Yearly Profit, Operating, Gross MarginsADMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

8

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), ADMA is creating value.
The number of shares outstanding for ADMA has been increased compared to 1 year ago.
ADMA has more shares outstanding than it did 5 years ago.
ADMA has a better debt/assets ratio than last year.
ADMA Yearly Shares OutstandingADMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
ADMA Yearly Total Debt VS Total AssetsADMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 24.37 indicates that ADMA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 24.37, ADMA belongs to the top of the industry, outperforming 94.99% of the companies in the same industry.
The Debt to FCF ratio of ADMA is 0.80, which is an excellent value as it means it would take ADMA, only 0.80 years of fcf income to pay off all of its debts.
ADMA's Debt to FCF ratio of 0.80 is amongst the best of the industry. ADMA outperforms 95.53% of its industry peers.
ADMA has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
ADMA's Debt to Equity ratio of 0.19 is on the low side compared to the rest of the industry. ADMA is outperformed by 69.59% of its industry peers.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.8
Altman-Z 24.37
ROIC/WACC2.73
WACC9.61%
ADMA Yearly LT Debt VS Equity VS FCFADMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

A Current Ratio of 6.58 indicates that ADMA has no problem at all paying its short term obligations.
ADMA has a Current ratio of 6.58. This is in the better half of the industry: ADMA outperforms 64.22% of its industry peers.
A Quick Ratio of 3.36 indicates that ADMA has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.36, ADMA is in line with its industry, outperforming 40.25% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.58
Quick Ratio 3.36
ADMA Yearly Current Assets VS Current LiabilitesADMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

8

3. Growth

3.1 Past

ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 2750.00%, which is quite impressive.
ADMA shows a strong growth in Revenue. In the last year, the Revenue has grown by 62.23%.
ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 70.84% yearly.
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%

3.2 Future

The Earnings Per Share is expected to grow by 31.81% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 21.03% on average over the next years. This is a very strong growth
EPS Next Y34.64%
EPS Next 2Y40.91%
EPS Next 3Y36.86%
EPS Next 5Y31.81%
Revenue Next Year20.23%
Revenue Next 2Y23.46%
Revenue Next 3Y24.42%
Revenue Next 5Y21.03%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ADMA Yearly Revenue VS EstimatesADMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B
ADMA Yearly EPS VS EstimatesADMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2

More info and screens

6

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 38.94, the valuation of ADMA can be described as expensive.
ADMA's Price/Earnings ratio is rather cheap when compared to the industry. ADMA is cheaper than 92.84% of the companies in the same industry.
When comparing the Price/Earnings ratio of ADMA to the average of the S&P500 Index (26.60), we can say ADMA is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 20.79, the valuation of ADMA can be described as rather expensive.
91.95% of the companies in the same industry are more expensive than ADMA, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 22.39. ADMA is around the same levels.
Industry RankSector Rank
PE 38.94
Fwd PE 20.79
ADMA Price Earnings VS Forward Price EarningsADMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 93.20% of the companies are valued more expensively.
Based on the Price/Free Cash Flow ratio, ADMA is valued cheaply inside the industry as 92.49% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 54.58
EV/EBITDA 32.25
ADMA Per share dataADMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.5 1 1.5

4.3 Compensation for Growth

ADMA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
ADMA has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as ADMA's earnings are expected to grow with 36.86% in the coming years.
PEG (NY)1.12
PEG (5Y)N/A
EPS Next 2Y40.91%
EPS Next 3Y36.86%

More info and screens

0

5. Dividend

5.1 Amount

ADMA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADMA BIOLOGICS INC

NASDAQ:ADMA (6/13/2025, 2:38:02 PM)

20.64

-0.96 (-4.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)08-06 2025-08-06
Inst Owners88.05%
Inst Owner Change2.69%
Ins Owners2.17%
Ins Owner Change2.27%
Market Cap4.93B
Analysts82
Price Target30.08 (45.74%)
Short Float %5.82%
Short Ratio3.67
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-19.83%
Min EPS beat(2)-31.17%
Max EPS beat(2)-8.5%
EPS beat(4)2
Avg EPS beat(4)8.19%
Min EPS beat(4)-31.17%
Max EPS beat(4)59.31%
EPS beat(8)4
Avg EPS beat(8)-15.66%
EPS beat(12)7
Avg EPS beat(12)-6.3%
EPS beat(16)10
Avg EPS beat(16)-4.09%
Revenue beat(2)1
Avg Revenue beat(2)-0.57%
Min Revenue beat(2)-3.31%
Max Revenue beat(2)2.16%
Revenue beat(4)3
Avg Revenue beat(4)7.87%
Min Revenue beat(4)-3.31%
Max Revenue beat(4)21.61%
Revenue beat(8)7
Avg Revenue beat(8)6.02%
Revenue beat(12)11
Avg Revenue beat(12)6.72%
Revenue beat(16)15
Avg Revenue beat(16)7.22%
PT rev (1m)14.57%
PT rev (3m)21.5%
EPS NQ rev (1m)-7.69%
EPS NQ rev (3m)0%
EPS NY rev (1m)-7.04%
EPS NY rev (3m)-4.69%
Revenue NQ rev (1m)1.48%
Revenue NQ rev (3m)7.11%
Revenue NY rev (1m)2.09%
Revenue NY rev (3m)5.69%
Valuation
Industry RankSector Rank
PE 38.94
Fwd PE 20.79
P/S 10.73
P/FCF 54.58
P/OCF 48.68
P/B 13.2
P/tB 13.34
EV/EBITDA 32.25
EPS(TTM)0.53
EY2.57%
EPS(NY)0.99
Fwd EY4.81%
FCF(TTM)0.38
FCFY1.83%
OCF(TTM)0.42
OCFY2.05%
SpS1.92
BVpS1.56
TBVpS1.55
PEG (NY)1.12
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 40.5%
ROE 55.37%
ROCE 33.26%
ROIC 26.28%
ROICexc 31.16%
ROICexgc 31.49%
OM 33.1%
PM (TTM) 45.01%
GM 52.58%
FCFM 19.65%
ROA(3y)4.32%
ROA(5y)-9.88%
ROE(3y)-2.53%
ROE(5y)-28.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y226.2%
GM growth 5YN/A
F-Score7
Asset Turnover0.9
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.8
Debt/EBITDA 0.45
Cap/Depr 138.39%
Cap/Sales 2.38%
Interest Coverage 11.85
Cash Conversion 63.28%
Profit Quality 43.66%
Current Ratio 6.58
Quick Ratio 3.36
Altman-Z 24.37
F-Score7
WACC9.61%
ROIC/WACC2.73
Cap/Depr(3y)120.67%
Cap/Depr(5y)186.15%
Cap/Sales(3y)4.32%
Cap/Sales(5y)11.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)2750%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y34.64%
EPS Next 2Y40.91%
EPS Next 3Y36.86%
EPS Next 5Y31.81%
Revenue 1Y (TTM)62.23%
Revenue growth 3Y74.04%
Revenue growth 5Y70.84%
Sales Q2Q%40.22%
Revenue Next Year20.23%
Revenue Next 2Y23.46%
Revenue Next 3Y24.42%
Revenue Next 5Y21.03%
EBIT growth 1Y243.41%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year61.1%
EBIT Next 3Y43.62%
EBIT Next 5Y35.99%
FCF growth 1Y247.45%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y309.9%
OCF growth 3YN/A
OCF growth 5YN/A